Document Detail


Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
MedLine Citation:
PMID:  21883324     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background  Sorafenib is the new reference standard for patients with advanced hepatocellular carcinoma (HCC). Aim  To identify prognostic factors in sorafenib-treated HCC patients and to evaluate outcomes with respect to liver function. Methods  In this retrospective study, 148 HCC patients received sorafenib 400 mg b.d. across 11 Austrian institutions. Seventy-eight HCC patients who received best supportive care (BSC) in the pre-sorafenib era served as a control. Results  In sorafenib-treated patients, low baseline α-fetoprotein, low Child-Pugh (CP) score, compensated cirrhosis, and low baseline aspartate aminotransferase (AST) were associated with significantly longer overall survival (OS) on univariate analysis. CP score and baseline AST remained independent prognostic factors on multivariate analysis. In patients with Barcelona Clinic liver Cancer (BCLC) stage B or C HCC (sorafenib: n = 139; BSC: n = 39), CP-A patients had a median OS of 11.3 (sorafenib [n = 76]) vs. 6.4 (BSC [n = 17]) months (P = 0.010), and CP-B patients had a median OS of 5.5 (sorafenib [n = 55]) vs. 1.9 (BSC [n = 22]) months (P = 0.021). In the sorafenib group, median OS according to baseline AST was 11.8 (<100 U/L [n = 58]) vs. 3.9 (≥100 U/L [n = 15]) months for CP-A patients (P = 0.127), and 6.5 (<100 U/L [n = 33]) vs. 2.1 (≥100 U/L [n = 21]) months for CP-B patients (P = 0.011). There was no survival difference between sorafenib and BSC in patients with BCLC stage D HCC (1.5 vs. 1.4 months; P = 0.116). Conclusions  Sorafenib was associated with improved survival in both CP-A and CP-B patients. In CP-B patients, baseline AST may be helpful in determining which patients are most likely to benefit from sorafenib.
Authors:
M Pinter; W Sieghart; F Hucke; I Graziadei; W Vogel; A Maieron; R Königsberg; A Weissmann; G Kornek; J Matejka; R Stauber; R Buder; B Grünberger; M Schöniger-Hekele; C Müller; M Peck-Radosavljevic
Related Documents :
3290754 - Phase ii trial of mitoxantrone in advanced gastric cancer.
19935794 - Sorafenib in patients with advanced biliary tract carcinoma: a phase ii trial.
14672404 - Phase i trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen...
3178154 - Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors.
8604244 - Pentostatin (2'-deoxycoformycin, dcf) in patients with low-grade (b-t-cell) and interme...
11578404 - Long-term survival and prognostic factors in advanced epithelial ovarian cancer with sp...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-24
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  -     ISSN:  1365-2036     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-9-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Affiliation:
Department of Gastroenterology and Hepatology, AKH & Medizinische Universität Wien, Austria. Department of Gastroenterology and Hepatology, Medizinische Universität Innsbruck, Austria. Fourth Medical Department, KH Elisabethinen Linz, Austria. Kaiser Franz Josef-Spital, Third Medical Department, Centre for Oncology and Hematology, CEADDP, Applied Cancer Research, Institution for Translational Research Vienna (ACR-ITR VIEnna), and Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), Vienna, Austria. Department of Oncology and Hematology, Wilhelminenspital Wien, Austria. Department of Oncology, AKH & Medizinische Universität Wien, Austria. Department of Gastroenterology & Hepatology, LKH & Medizinische Universität Graz, Austria. Department of Internal Medicine, KH Barmherzige Brüder Linz, Austria. Department of Internal Medicine, KH Barmherzige Brüder Wien, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Next Document:  Cycled enteral antibiotics reduce sepsis rates in paediatric patients on long-term parenteral nutrit...